Bayer to Present Data on Investigational Oncology Compounds at 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Presentations highlight Bayer’s growing oncology pipeline
Wayne, NJ, May 18, 2011 – Bayer HealthCare Pharmaceuticals, Inc. announced today that data evaluating several of its investigational oncology compounds will be presented in a scientific forum at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7, in Chicago, IL.
"Bayer has built a pipeline of oncology compounds, including several in late-stage development, and our researchers are working tirelessly to advance their development," said Kemal Malik, MD, Head of Global Development and member of the Bayer HealthCare Executive Committee. "At ASCO, we are presenting data from studies evaluating these compounds."
Bayer-sponsored Phase II and III studies evaluating the investigational compounds in Bayer’s pipeline being presented at ASCO include:
Radium-223 Chloride
Alkaline Phosphatase (ALP) Normalization and Overall Survival in Patients With Bone Metastases From Castration-Resistant Prostate Cancer (CRPC) Treated with Radium- 223 (Alpharadin)
- Abstract #4620, Genitourinary Cancer Poster Session
- Sunday, June 5, 8:00 am - 12:00 pm, Hall A, Poster Board 7D
Radium-223 chloride is an investigational agent and is not approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) or other Health Authorities.
About Oncology at Bayer
Bayer is committed to advancing the science of cancer, and translating this science into
therapies that can help people with cancer live longer. With several compounds in clinical
development, Bayer’s oncology portfolio demonstrates the Company’s commitment to
developing innovative cancer therapies.
About Bayer HealthCare Pharmaceuticals Inc.
Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of
Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's
leading, innovative companies in the healthcare and medical products industry, and
combines the activities of the Animal Health, Consumer Care, Diabetes Care, and
Pharmaceuticals divisions. As a specialty pharmaceutical company, Bayer HealthCare
Pharmaceuticals provides products for Diagnostic Imaging, General Medicine,
Hematology, Neurology, Oncology and Women’s Healthcare. The company's aim is to
discover and manufacture products that will improve human health worldwide by
diagnosing, preventing and treating diseases.
# # #
BAYER (reg’d) and the Bayer Cross (reg’d) are trademarks of Bayer.
Contact:
David Freundel, 973-305-5310
E-Mail: david.freundel@bayer.com
Forward-Looking Statements This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
